Last reviewed · How we verify
K27M peptide
At a glance
| Generic name | K27M peptide |
|---|---|
| Sponsor | Sabine Mueller, MD, PhD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma (PHASE1)
- H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- K27M peptide CI brief — competitive landscape report
- K27M peptide updates RSS · CI watch RSS
- Sabine Mueller, MD, PhD portfolio CI